🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

St Jude in $39.25 million shareholder settlement over heart devices

Published 07/08/2016, 12:39 PM
Updated 07/08/2016, 12:50 PM
St Jude in $39.25 million shareholder settlement over heart devices
ABT
-

By Jonathan Stempel

(Reuters) - St. Jude Medical Inc has reached a $39.25 million class action settlement with shareholders to resolve claims it downplayed the possible dangers associated with a product used to connect implantable defibrillators to patients' hearts.

The preliminary settlement, disclosed Thursday with the U.S. District Court in Minneapolis, requires a judge's approval.

It resolves claims that St. Jude inflated its stock price by concealing risks revealed in a November 2012 U.S. Food and Drug Administration report about its Durata lead, a cable linking the heart to a defibrillator.

St. Jude used a material called Optim to insulate Durata and help preserve its ability to deliver needed electric shocks.

But the FDA report raised questions about whether St. Jude had properly tested Durata, and whether the lead could face problems similar to what prompted a 2011 recall of Riata, a lead that was prone to failure because the insulation wore away.

St. Jude's share price fell more than 12 percent on Nov. 21, 2012, the day after the FDA report was released, wiping out roughly $1.3 billion of its market value.

The St. Paul, Minnesota-based company denied liability in agreeing to the settlement, which averted a February 2017 trial.

St. Jude had no immediate comment on Friday. In a May 4 regulatory filing, it said it had not taken a charge for a possible settlement. The company reported $880 million of profit on net sales of $5.54 billion for 2015.

Abbott Laboratories (NYSE:ABT) agreed in April to buy St. Jude for about $25 billion.

Forsta AP-Fonden of Sweden and Danske Invest Management A/S of Denmark led the class action on behalf of St. Jude shareholders from Feb. 5, 2010 to Nov. 20, 2012.

Their law firms, Kessler Topaz Meltzer & Check and Motley Rice, plan to request up to $9.81 million in legal fees plus up to $2.9 million for costs.

Gregory Castaldo, from Kessler Topaz, and Gregg Levin, from Motley Rice, on Friday said they were pleased to settle.

The case is Forsta AP-Fonden et al v. St. Jude Medical Inc et al, U.S. District Court, District of Minnesota, No. 12-03070.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.